Purpose: Proton minibeam radiotherapy using submillimeter beam dimensions allows to enhance tissue sparing in the entrance channel by spatial fractionation additionally to advantageous proton depth dose distribution. In the entrance channel, spatial fractionation leads to reduced side effects compared to conventional proton therapy. The submillimeter sized beams widen with depth due to small angle scattering and enable therefore, in contrary to x-ray microbeam radiation therapy (MRT), the homogeneous irradiation of a tumor. Proton minibeams can either be applied as planar minibeams or pencil shaped with an additional possibility to vary between a quadratic and a hexagonal arrangement for pencil minibeams.
INTRODUCTION
Ionizing radiation is used for 50-60 % of cancer patients as a curative approach. Targeting a tumor with external radiation intentionally causes damage in the tumor as well as unintentionally in the healthy tissue that is traversed by radiation. Thus, side effects are induced within the irradiated healthy tissues, which often limit the deposited dose in the target volume. Therefore, side effects decrease the chance of cure and the patients' well-being. Radiation therapy would substantially improve if radiation-induced toxicities in the healthy tissues will be reduced.
In modern state of the art radiotherapy, fractionation and intensity-modulated radiotherapy are used to control side effects. In addition, intensity-modulated particle therapy, especially proton or carbon ion therapy utilizing pencil beams of millimeter size, has proven to reduce the energy deposited in the healthy tissue and thus further reduces side effects. A current research topic to improve radiotherapy even further is spatial fractionation. In spatial fractionation, submillimeter sized planar or pencil beams ("minibeams") are used to spare large parts of the irradiation field from ionizing radiation. Even though, detailed mechanisms involved in the tissue sparing of small beams of radiation 1 are not fully understood, it is assumed to be based on the principles of the dose-volume effect. 2 While the minibeams obtain enhanced doses, the spared, nonirradiated cells can contribute to a faster recovery of the strongly irradiated parts. Additional effects as 'the prompt microscopic biological repair effect' might add to the higher dose tolerances of irradiated tissues by a fast repair of the capillary blood vessels. 3, 4 Finally, the fast capillary repair might also be based on a dose-volume effect with two mechanisms involved. The first is the regeneration of the microvasculature by forming capillary "bridges" through the irradiated minibeam paths. 5 The second effect is the high resistance of capillaries to tiny beams due to their high ability to keep the endothelial layer confluent. 3 Spatial fractionation with millimeter sized beams was already introduced by Alban K€ ohler in 1909 . 6 Although the potential of a spatially fractionated irradiation for reducing side effects in the healthy tissue was clearly demonstrated, 1, [7] [8] [9] [10] it was mainly used for palliative rather than curative cancer treatment. 11 Due to the reason that the tumor also obtained a millimeter sized, spatially fractionated dose 9, 10 caused a tumor growth delay but not a complete tumor elimination. Currently, there are two different concepts of spatial fractionation to simultaneously profit from reduced side effects in the healthy tissue and a complete tumor control.
On the one hand, there is the invention of the microbeam radiation therapy (MRT) with planar, micrometer sized photon beams from the Brookhaven National Laboratory (New York, NY, USA) 12 and its further development in Grenoble, France at the European Synchrotron Radiation Facility (ESRF). [13] [14] [15] Based on the same principle, ions, especially heavy ions which barely spread in tissue, have been suggested for spatially fractionated therapy with their intrinsically favorable depth dose distribution. 16 On the other hand, there is the proton minibeam radiotherapy (pMBRT) concept introduced by Zlobinskaya et al. 17 and Prezado et al. 18 Both concepts have in common that spatial fractionation is used to spare healthy tissue in the entrance channel. However, the approaches differ in obtaining complete tumor control.
MRT uses arrays with a few tens of micron thick, highly energetic (50-600 keV), planar photon beams in distances of 50-400 lm and a certain valley dose level in between the microbeams. With regard to the tumor irradiation and its control, the beam structure from MRT is maintained in the target volume with peaks and valleys. The same applies for the heavy ion minibeam therapy except of the larger beam sizes of a few hundreds of microns and distances in the submillimeter to millimeter range. 19 Valley doses and peak-to-valley dose ratios (PVDR) are adjusted to obtain optimized tissue sparing and simultaneous tumor control. Valley doses are normally lower than required to completely stop proliferation of all malignant cells. But tumors can be slowed down in growing or even controlled, 20 thanks to mal-developed vascular structures and lead MRT to be suggested for clinical trials. 21 The search for an optimum configuration of dose levels and variations of PVDR in the tumor to simultaneously achieve the best tumor control and reduce side effects is one of the most crucial challenges of MRT. The MRT approach might only be applicable for special but important tumor entities like brain tumors due to the requirement of the specific vascular situation needed for tumor control. There are also options to make MRT generally applicable by covering the tumor completely with the dose required to eliminate all tumor stem cells by using multiple irradiation fields interlacing from several directions. 22 However, technical constraints and the problem of moving organs when applying micrometer sized, interlacing planar photon beams may prevent the application of this option.
In contrary to MRT, the pMBRT uses the conventional approach to control a tumor since it aims for a homogeneous dose distribution in the tumor and can therefore benefit from long-standing clinical experiences regarding dose requirements to control a tumor. 17, 18, 23 Any patient suffering from deep lying tumors might profit. The homogeneous dose distribution in the tumor is achieved by multiple small angle scattering from the spatially fractionated proton beam in the entrance channel, even if only one direction of irradiation is used. 17, 23 The small beams in the superficial layers increase in size with depth and by adjusting the center-to-center beam distances, the finally overlapping beams form the homogeneous dose distribution in the target. The mean dose to stop the malignant cells from proliferating fixes the dose parameter of the pMBRT. The first experimental results in a human skin model 17 and the first proof of principle experiment in an animal study 23 have shown the tremendous tissue sparing potential the proton minibeam radiotherapy. A dosimetric evaluation has also been carried out at a clinical proton center. 24 The proton minibeams are chosen slightly larger than the x-ray beams in MRT, but still on submillimeter scale using interbeam distances of a few millimeters. Protons are either applied as planar minibeams 18 or as pencil minibeams. 17, 23 The same principle can also be applied for heavier ions as He or Li, but the higher particles momenta decrease the lateral spread. Smaller center-to-center distances of the minibeams and smaller minibeam sizes are required to spare healthy tissue and obtain homogeneous dose coverage within a tumor. 25 In this work, we want to characterize and compare two-dimensional arrangements of submillimeter proton pencil minibeams arranged either in a quadratic or a hexagonal pattern and a one-dimensional arrangement of planar minibeams as schematically shown in Fig. 1 , which all fulfill a dose homogeneity requirement within the tumor.
To assess the calculated dose distributions with respect to tissue sparing, we calculate the depth-dependent cell survival for a tumor treatment within a water phantom. The beams are assumed as Gaussian shaped and are generated via magnetic focusing as it has already been demonstrated in a preclinical experiment in a mouse model utilizing 20 MeV protons at the experimental facility SNAKE in Munich. 23 There is no physical limit to focus even 250 MeV protons to beam sizes of 0.1 mm in diameter. The advantage of a focused beam is a lower exposure to scattered protons and secondary neutrons in the valleys and next to the irradiated paths in comparison to collimated beams.
MATERIALS AND METHODS

2.A. Two-dimensional dose maps
Dose distributions are calculated using the software MATLAB. 26 By approximating a single minibeam by a Gaussian distribution, spatial dose distributions of minibeam scenarios depend on the beam size (given in standard Medical Physics, 44 (11), November 2017 deviations r) and the center-to-center distance (ctc) of the beams as defined in Fig. 1 . The minibeams are arranged on two-dimensional and one-dimensional lattice structures. Thus, the lateral dose distributions are defined for the planar line grid as
for the quadratic arrangement as
and for the hexagonal case as D 0 is the mean dose within a given x-y plane and k,l are the summation indices, which are representative for the location of the Gaussian beam on the used grid.
All dose distributions depend only on a single parameter r ¼ r ctc , which is the standard deviation normalized to the lattice constant ctc as defined in Fig. 1 . The dose distributions are plotted dimensionless using the normalized distanceŝ
The periodicity of the minibeam arrangements is used to restrict the dose calculations to one unit cell, which is representative for the whole dose distribution of each scenario if lateral restrictions are neglected. The two-dimensional dose distributions are calculated on ax Àŷ grid with pixel size of 0.005 9 0.005. A step size of 0.001 is used for the onedimensional dose distributions of planar minibeams for an improved binning (behavior). An infinite number of Gaussian beams contribute to the representative unit cell. We reduce this problem and calculate 16 9 16 Gaussian beams for the quadratic as well as for the hexagonal case (16 rows and 16 columns) and 17 Gaussian beams for the one-dimensional planar minibeams. The considered unit cell is centered within the calculated beam matrices. Thus, the contribution of all Gaussians outside this 16 9 16 matrix in the two-dimensional case and 17 planar beams in the one-dimensional case is less than 2.6 9 10 À18 D 0 for minibeam sizesr\0:6. For comparison, a broadbeam application is considered as a perfectly homogeneous dose distribution.
2.B. Three-dimensional treatment plans
For a direct comparison of the different beam arrangements, we calculate three-dimensional treatment plans in a water phantom dependent on the tumor thickness t, the depth of its proximal side d min and the ctc distances for the different minibeam arrangements. The tumor is situated at d min = 10 cm underneath the skin and has a thickness of t = 5 cm. The lateral expansion of the tumor is infinite to reduce the calculations to a representative unit cell as discussed in section 2.A. A tumor size and location-dependent dose reduction toward lateral edges in finite cases needs to be considered in a minibeam realization. Energy-dependent proton depth dose curves as well as lateral spread of protons for different depths are taken from the database LAP-CERR, 27, 28 which is based on GEANT4 29 Monte Carlo simulations for protons in water. The minibeam width r is composited of the initial beam size r 0 , chosen as 200 lm, and the lateral spread for protons from multiple scattering r sc as r ¼ ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi ffi r 2 0 þ r 2 sc p . Since the small angle scatter of protons dominates the beam size, beam divergences are neglected.
A homogeneous depth dose distribution is generated by a Spread Out Bragg Peak (hereafter SOBP), which is shown in Fig. 2 , for protons in the energy range from 117 to 148 MeV. The step size of the single Bragg peaks is~1 mm in depth (1-2 MeV steps) which can form a uniform depth dose, if an appropriate weighting is chosen. We determined the 
Medical Physics, 44 (11) Table I shows the weights of the single Bragg Peaks given relative to the Bragg peak of the beam with highest energy.
Two-dimensional lateral dose profiles for a certain depth are calculated after the composition of the SOBP. The SOBP delivers the mean dose D 0 , as defined in Eqs. (1)-(3), for the minibeam scenarios at all relevant depths. By taking the beam sizes from LAP-CERR and summing up, the dose distributions of the single energies according to the weighting factors yield the corresponding two-dimensional dose maps. The two-dimensional dose distributions are calculated between 10 and 160 mm in steps of 1 mm. In LAP-CERR, lateral spread data are not available for depths smaller than 10 mm in the water phantom, therefore defining the starting depth of the simulation.
Local cell survival fractions SF(x,y) in all depths of the phantom are evaluated from the dose distributions D(x,y) in the corresponding depth, applying the linear-quadratic (LQ) approach 30 SF(x,y) ¼ expðÀaDðx,yÞ À bD 2 ðx,yÞÞ:
The parameters a and b are the calculated mean values from all human cell survival data listed in the PIDE data collection, 31 The threshold dose is chosen to be D th = 6 Gy. While experimentally found in the range of several Gy up to 20 Gy, it is set close to the lower end of the typical range of D th values to see the maximum differences of the LQ and LQ-LC models. The parameters a and b are the same as for the linear-quadratic model [Eq. 4a].
RESULTS AND DISCUSSION
3.A. Homogeneity constraints for minibeams
The center-to-center distance between proton minibeams should be as large as possible to minimize side effects, but should be small enough to obtain a homogeneous dose distribution within the target volume. 
These values may be taken as a general basis for treatment planning using proton minibeams since the results can be applied for any depth depending just on the beam size at the considered depth. Consequently, if beam sizes r within the tumor are known, the ctc distances can be extracted from ther values to maintain homogeneity within the tumor tissue. The distances vary due to the applied geometry as
To treat a tumor of thickness t, with its front at d min , the homogeneity criteria [Eq. 5] must be fulfilled at all depths between d min and d min + t. The depth dose can be achieved as in normal proton therapy by the generation of a Spread Out Bragg Peak (SOBP), where several beams with different energies contribute. It is a sufficient condition for homogeneity, if the smallest beam size, which is obtained for the protons with the highest energy at minimum tumor depth d min , fulfills the homogeneity condition. All other beam sizes of less energetic protons are larger at this depth due to larger multiple angular scattering. Thus, these beams will fulfill the homogeneity constraints, too. Similar holds true for larger depths, where all beams are scattered more than at d min . In  Fig. 4 , the maximum ctc distances that can be chosen to fulfill the homogeneity constraint in a tumor are plotted in dependence of the tumor depths t and the depth of its front side d min .
With regard to tissue sparing, larger beam distances for the hexagonal (~14%) or the planar (~8%) in comparison to the quadratic arrangement might be of advantage in two different aspects. On the one hand, concerning a clinical realization, larger distances result in fewer minibeam spots to cover equal tumor sizes, leading to faster treatments and therefore lower costs. On the other hand, the tissue sparing might increase for larger ctc distances. Since tissue sparing is barely quantifiable with regard to a dose application, the calculated treatment plans presented in the following section allow to calculate a mean cell survival fraction from the dose distributions.
3.B. Three-dimensional dose simulation
Three-dimensional dose distributions for a tumor situated 10-15 cm underneath the skin are optimized to compare the dose distributions obtained from the different proton minibeam arrangements and a conventional broadbeam irradiation. In a first step, the proper SOBP with its varying energies and depth dose distributions are calculated as needed for a proton broadbeam treatment with constant lateral dose profile. In a second step, the same energies are used to calculate the minimum beam spreads at d min = 10 cm using the initial beam size of r 0 = 0.2 mm for all minibeam cases as well as using additionally r 0 = 0.075 mm for the planar case. The optimized ctc distances are calculated according to the constraints of Eqs. (6)- (8) for the different minibeam arrangements. As a result, the ctc distances are 3.405 mm for the quadratic, 3.895 mm for the hexagonal and 3.665 mm for the planar case assuming the initial beam spread r 0 = 0.2 mm. A change of the impinging planar beam size to r 0 = 0.075 mm does not substantially change the required ctc distance (e.g., 3 .645 mm for the planar case).
Lateral dose distributions as obtained at 1 mm, 33 mm, 66 mm, and 100 mm depth for the SOBP are shown in Fig. 5 . Figure 6 shows profiles from the line cuts of the lateral dose distributions as partially marked in Fig. 5 . depths suggest benefits not only in the superficial layers, but also in deeper layers. At the tumor entrance, the dose reaches a modulation within the homogeneity criteria of Eq. (5) in all cases. The minimum and maximum appearing dose values are presented over depth in Fig. 7 in order to quantitatively compare the different minibeam scenarios.
It shows the depth dependencies of the dose extrema in more detail. All minibeam scenarios follow a similar behavior with the largest maximum doses for the hexagonal case and the lowest minimum doses for the quadratic arrangement. The planar arrangements show a lower modulation than the pencil minibeam arrangements.
For all the minibeam scenarios, the SOBP of a conventional proton treatment plan gives the total number of applied protons and thus the mean dose value at any depth. Consequently, the mean dose increases with depth although the maximum dose values of the minibeam arrangements decrease. Thus, independent of the initial beam size, the largest total dose is deposited within the tumor. Smaller initial beam sizes increase the PVDR ratios, especially in the superficial layers, while the mean dose stays the same at each depth.
3.C. Cell survival
In this final section, simulated dose distributions are assessed on the basis of a calculated clonogenic cell survival. The mean cell survival is computed from the simulated dose distributions for 2 and 10 Gy deposited homogeneously in the tumor. Cell survival is calculated using both, the LQ-model The depth-dependent cell survival is plotted for the different minibeam and the homogeneous treatment plans in Fig. 8 .
The calculations show that the cell death within the tumor stays the same for all applied irradiation conditions. Thus, the same tumor control can be expected after irradiation with the same dose average. All minibeam treatment plans, however, result in a higher cell survival in the healthy tissue with the greatest benefits in the superficial layers. This is caused by the geometrical sparing of the tissue. While in a broadbeam irradiation, all cells suffer from radiation damage with the same survival probability, up to 90 % of the cells (dependent on the boundary conditions, especially initial beam size and beam shape) are barely hit by radiation within the minibeam irradiations. Hence, all the cells in the low dose surrounding of the minibeams survive, leading to survival rates of up to 90 %. The lateral scattering reduces this geometrical effect until the survival curves finally merge with that of the broadbeam treatment plan at a depth of~7-8 cm.
For the 10 Gy tumor dose, the maximum benefits in comparison to a broadbeam irradiation are found for the hexagonal pencil beam arrangement with up to 90 percentage points larger cell survival. This is followed by a slight reduction in cell survival for the quadratic minibeam case at the smallest depth of 10 mm considered in the calculations. Although the planar minibeam irradiation also shows up to~70 percentage points enhanced cell survival compared to broad beam irradiation (dashed, magenta marked line), the enhancement is substantially smaller than for the pencil minibeam arrangements.
The 2 Gy tumor irradiation behaves similar as the 10 Gy tumor irradiation, although the absolute differences are not as large. The hexagonal pencil minibeam irradiation shows the most promising outcome, with up to~30 percentage points larger cell survival in comparison to the homogeneous approach. The planar minibeams with the 0.2 mm initial beam size (solid, magenta marked line) show again the lowest cell survival for minibeams, with about 20 percentage points higher cell survival than the broad beam irradiation.
The comparison of the 10 Gy and 2 Gy tumor dose curves shows that the cell survival is almost equal in the entrance channel, although the doses differ by a factor of 5. The reason is the geometrical sparing: irradiated cells have almost no survival probability within the minibeams, since the maximum dose is~60 Gy when applying minibeams for a homogeneous tumor dose as low as 2 Gy. The large "superficial" survival fraction is thus mainly defined by the area irradiated with doses much lower than the mean dose, which is geometrically defined. The cell survival enhancements decrease approximately linear with depth for all minibeam treatment plans until a depth of 6 cm and begin to approach the broadbeam scenario with a final merging depth of 8 cm.
Comparing just the minibeam scenarios, the pencil minibeams with hexagonal and quadratic arrangement behave different than the planar irradiations. The planar minibeams of smaller initial beam size lead to enhanced cell survival at very superficial layers, but converge quickly (~4 cm depth) to that of the bigger initial beam sized planar irradiation. The pencil minibeams, however, show substantial higher cell survival at all depths than both planar minibeam scenarios with some (< 5 percentage points), but not much more tissue sparing for the hexagonal arrangement compared to the quadratic.
CONCLUSION
Treatment plans are calculated for a realistically dimensioned tumor scenario in a water phantom to assess the different geometrical mini-and broadbeam arrangements on a cell survival basis. The determination of the homogeneity conditions by means of a normalizedr is the basis of a proton minibeam radiotherapy. The different minimalr values required to fulfill the homogeneity constraint arise from geometry. They allow to increase the beam distances for the hexagonal minibeam arrangement by~14% in comparison to a quadratic pencil minibeam arrangement, with an additional slight advantage in tissue sparing.
The presented results are an indication of the potential provided by a spatially fractionated therapy using proton minibeams. In a human body, different tissues are penetrated by the protons, leading to a variation of the corresponding a and b values. Nevertheless, the sparing of healthy tissue is mainly caused by geometrical sparing of irradiated volumes. Thus, the result of the used survival model gives a good approximation of the expected beneficial effects. Biological responses such as inflammation or bystander effects are not taken into consideration in the used model. Additional adverse biological effects appearing from the extreme doses are also expected to have little impact on the overall side effects, since the number of cells hit by dose extrema is low. This is confirmed by previous biological investigations into minibeam treatment, where no indication of short-term adverse effects 15, 21 has been found. The presented data show that the lateral spread of the protons can bring a minibeam irradiation close to that of conventional pencil beam scanning. Similar spot-to-spot distances are used in proton minibeam radiotherapy, especially in case of deep laying tumors, e.g., situated deeper than 10 cm underneath the skin (see Fig. 4 ). However, for some extreme scenarios as large tumors close to the surface (e.g., a 5 cm thick tumor situated 4 cm below the skin), the number of minibeams to be irradiated will grow since ctc distances as low as 1 mm need to be applied. This would make minibeam irradiation, especially its delivery of the required number of beam spots within a reasonable time span, very ambitious. The same applies for precision accuracies in pMBRT. While the beam spreads to several millimeter spot size for deep laying tumors, the placement accuracy comes close to the requirements in conventional proton pencil beam scanning. Contrary to deep laying tumors, current technical possibilities are exceeded for targets closer to the surface, which entail smaller, more critical beams to be overlapped.
For future projects, the results suggest to concentrate more on pencil proton minibeams than on any planar proton minibeam therapy to maximize the benefits of spatial fractionation. To implement pMBRT in clinics, it will be necessary to develop new techniques in beam delivery as well as placement precision to use a proton minibeam therapy to its full extent. Other challenges as they are found in proton therapy, e.g., target motion, will also increase if proton minibeams are applied. However, a detailed discussion of technical implementation is out of the scope of this manuscript, which is dedicated to show the potential of a spatially fractionated proton therapy on a computational level. and Research, by the DFG-Cluster of Excellence 'MunichCentre for Advanced Photonics' and by the Maier Leibnitz Laboratory Munich. We kindly thank Prof. Dr. J.J. Wilkens for enabling the access to the LAP-CERR database.
CONFLICTS OF INTEREST
The authors have no relevant conflicts of interest to disclose.
a)
Author to whom correspondence should be addressed. Electronic mail: matthias.sammer@unibw.de; Telephone: +49 (0) 89 6004 3515.
